IRCT20130501013194N4 IRCT 2019-12-28 Hamedan University of Medical Sciences The effect of Oleoyl ethanolamide (OEA) supplementation in patients with acute ischemic brain stroke The effect of Oleoyl ethanolamide (OEA) supplementation on blood hematological parameters, lipid profile, biomarkers of oxidative stress and inflammatory parameters in the blood of patients with acute ischemic brain stroke 2020-01-20 anticipated 40 Complete https://irct.ir/trial/44304 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This is an interventional study with a randomized controlled trial study design. In this study, 40 patients referred to Sina Hospital of Hamadan (consecutively) with diagnosis of acute ischemic stroke physician will be included in the study. In this study, patients were randomly divided into two groups of Oleoyl ethanolamide and placebo with Allocation Concealment by random number table and based on their group of supplements receive the relevant for two months. They will receive a computer code. The personal code of any participant in this course of treatment is not disclosed. Treatment codes are revealed at the end of the study after the database is closed, Blinding description: Participants receive the relevant supplements for two months after obtaining written consent from the group in which they are located. They will receive a computer code. The personal code of any participant in this course of treatment is not disclosed. Treatment codes are revealed at the end of the study after the database is closed. Capsules and placebo are similar in appearance, so clinical caregivers, researchers, outcome assessors and data analysts and the Committee on Safety and Data Monitoring know patients only by code and do not know which patient received the supplement or placebo. 2 Acute ischemic brain stroke. Intervention 1: Intervention group: They take one oleoyl ethanolamide supplement (200 mg) daily for two months. Supplements are made by Karen. Intervention 2: Control group: They receive a placebo capsule daily (a capsule that is not Oleoyl ethanolamide but patients are not told) for 2 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information.